Infectious diseases Archives - Page 13 of 33

Infectious diseases

Clinical Articles

Cruise ships are back and carrying COVID. No, it’s not 2020. But here’s what needs to happen next

Cruise ships carrying passengers with COVID are back in the news...

Infectious diseases

Clinical Articles

From Centaurus to XBB: your handy guide to the latest COVID subvariants (and why some are more worrying than others)

The Omicron variant of concern has splintered into multiple subvariants.

Expert/s: Healthed

Infectious diseases

Podcasts

COVID update – Bivalent jab, new variants and herd immunity

The bivalent vaccines, the new variant alert for Ba.2.75 and Ba.4.6, and herd immunity predictions and implications

Expert/s: Prof Kristine Macartney

Infectious diseases

Clinical Articles

If you think scrapping COVID isolation periods will get us back to work and past the pandemic, think again

COVID is an exceptional disease and was at its deadliest this year, causing more deaths in Australia between June and August 2022 than at any other time.

Expert/s: Prof Raina MacIntyre, Prof Nancy Baxter, Prof Brendan Crabb AC

Infectious diseases

Videos

Understanding the advantages of cell-based influenza vaccines

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).

Expert/s: Prof Paul Griffin

Infectious diseases

Podcasts

Lagevrio questions, mRNA jab misunderstandings and nasal vaccines coming

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

Expert/s: Prof Paul Griffin

Infectious diseases

Podcasts

Bivalent vaccines and other recent developments

The elimination of isolation periods and mask mandates, and an update on the vaccination landscape, including recently approved jabs, the bivalent vaccine, and vaccination for children

Expert/s: Prof Nancy Baxter

Infectious diseases

Clinical Articles

Vaccines build on herd immunity

Almost three years into the pandemic, the widespread uptake of vaccines in Australia, together with the large rate of infection from the Omicron variant has created very good population immunity, according to Professor Kristine Macartney from the National Centre for Immunisation Research.

Expert/s: Rosalyn Page

Infectious diseases

Clinical Articles

Preparing for the next COVID wave

GPs should plan antivirals for high- risk patients

Expert/s: Ben Falkenmire

Infectious diseases

Clinical Articles

Here’s another type of COVID test to get your head around. But is this new home kit worth the cost?

A new type of COVID test is set to be available from November for Australians to use at home.

Expert/s: Healthed

Infectious diseases

Podcasts

Practical guide to using COVID antivirals in primary care

Navigating interactions... it’s easier than it first looks, and how antivirals are an important part of the management strategy to reduce the chances of severe illness and hospital admissions

Expert/s: Dr Alexander Padiglione

Infectious diseases

Clinical Articles

The best COVID antivirals to prescribe

Under national guidelines, patients with COVID at high risk of serious illness should be prescribed nirmatrelvir (Paxlovid) by GPs, with the less effective molnupiravir (Lagevrio) a second-line option.

Expert/s: Ben Falkenmire

Infectious diseases

Cruise ships are back and carrying COVID. No, it’s not 2020. But here’s what needs to happen next

Cruise ships carrying passengers with COVID are back in the news...

From Centaurus to XBB: your handy guide to the latest COVID subvariants (and why some are more worrying than others)

The Omicron variant of concern has splintered into multiple subvariants.

COVID update – Bivalent jab, new variants and herd immunity

The bivalent vaccines, the new variant alert for Ba.2.75 and Ba.4.6, and herd immunity predictions and implications

If you think scrapping COVID isolation periods will get us back to work and past the pandemic, think again

COVID is an exceptional disease and was at its deadliest this year, causing more deaths in Australia between June and August 2022 than at any other time.

Understanding the advantages of cell-based influenza vaccines

Lagevrio questions, mRNA jab misunderstandings and nasal vaccines coming

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

Bivalent vaccines and other recent developments

The elimination of isolation periods and mask mandates, and an update on the vaccination landscape, including recently approved jabs, the bivalent vaccine, and vaccination for children

Vaccines build on herd immunity

Almost three years into the pandemic, the widespread uptake of vaccines in Australia, together with the large rate of infection from the Omicron variant has created very good population immunity, according to Professor Kristine Macartney from the National Centre for Immunisation Research.

Preparing for the next COVID wave

GPs should plan antivirals for high- risk patients

Here’s another type of COVID test to get your head around. But is this new home kit worth the cost?

A new type of COVID test is set to be available from November for Australians to use at home.

Practical guide to using COVID antivirals in primary care

Navigating interactions... it’s easier than it first looks, and how antivirals are an important part of the management strategy to reduce the chances of severe illness and hospital admissions

The best COVID antivirals to prescribe

Under national guidelines, patients with COVID at high risk of serious illness should be prescribed nirmatrelvir (Paxlovid) by GPs, with the less effective molnupiravir (Lagevrio) a second-line option.

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.

Infectious diseases

Cruise ships carrying passengers with COVID are back in the news...

The Omicron variant of concern has splintered into multiple subvariants.

The bivalent vaccines, the new variant alert for Ba.2.75 and Ba.4.6, and herd immunity predictions and implications

COVID is an exceptional disease and was at its deadliest this year, causing more deaths in Australia between June and August 2022 than at any other time.

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

The elimination of isolation periods and mask mandates, and an update on the vaccination landscape, including recently approved jabs, the bivalent vaccine, and vaccination for children

Almost three years into the pandemic, the widespread uptake of vaccines in Australia, together with the large rate of infection from the Omicron variant has created very good population immunity, according to Professor Kristine Macartney from the National Centre for Immunisation Research.

GPs should plan antivirals for high- risk patients

A new type of COVID test is set to be available from November for Australians to use at home.

Navigating interactions... it’s easier than it first looks, and how antivirals are an important part of the management strategy to reduce the chances of severe illness and hospital admissions

Under national guidelines, patients with COVID at high risk of serious illness should be prescribed nirmatrelvir (Paxlovid) by GPs, with the less effective molnupiravir (Lagevrio) a second-line option.

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Sign up for a free Healthed account

Extra Details

PASSWORD RESET

Discover

Healthed

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.